Quantcast

Latest schizophrenia Stories

2014-03-28 12:26:07

DUBLIN, March 28, 2014 /PRNewswire/ -- Dublin - Research and Markets ( http://www.researchandmarkets.com/research/cw7xqm/investigation) has announced the addition of the "Investigation Report on China's Aripiprazole Market, 2009-2018" [http://www.researchandmarkets.com/research/cw7xqm/investigation ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Schizophrenia is a common mental disorder. Data shows that mental illness has...

2014-03-27 08:30:09

NEW YORK, March 27, 2014 /PRNewswire/ -- Elsevier [http://www.elsevier.com ], a world-leading provider of scientific, technical and medical information products and services, today announced the launch of Schizophrenia Research: Cognition [http://www.schizrescognition.com ], a new open access journal dedicated to publishing original research, concise research reports, brief reports, letters to the editor, and review papers addressing the role of cognitive functioning in...

2014-03-26 23:01:29

The Firm is investigating Risperdal lawsuits on behalf of men and boys who developed gynecomastia (male breast growth), allegedly due to their use of Risperdal. New York, New York (PRWEB) March 26, 2014 Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) continue to move forward in a mass tort proceeding currently underway in Pennsylvania’s Philadelphia Court of Common Pleas, Bernstein Liebhard LLP reports. According to court documents, the proceeding’s next meeting has been...

2014-03-20 08:29:49

Independent Data Monitoring Committee Recommends Halting Trial and Unblinding Data Based on Treatment Efficacy TITUSVILLE, N.J., March 20, 2014 /PRNewswire/ -- Janssen Research & Development, LLC announced today that following an Independent Data Monitoring Committee (IDMC) recommendation based on positive efficacy, it has halted early a Phase 3 clinical study of paliperidone palmitate 3-month formulation, an investigational treatment for symptoms of schizophrenia in adults. "We are...

2014-03-15 23:04:17

Flood Law Group today announced that they are now actively investigating claims on behalf of men and boys who have been diagnosed with gynecomastia after taking the prescription drug Risperdal. According to the FDA label for Risperdal, in some cases, the drug can cause a reduction in pituitary secretion of gonadotropin, possibly resulting in gynecomastia. Washington D.C. (PRWEB) March 14, 2014 Flood Law Group announced today that they are now actively investigating potential claims on...

2014-03-13 08:29:52

MOUNTAIN VIEW, Calif. and BARCELONA, Spain, March 13, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) and Ferrer today announced that ADASUVE(®) inhalation powder, pre-dispensed (loxapine) is now available in Romania. Ferrer is Alexza's commercial partner for ADASUVE in the European Union (EU), Latin America and the Commonwealth of Independent States countries. Ferrer is commercializing the product in Romania through a distribution agreement with Galenica, S.A....

2014-03-11 23:33:34

A pharmaceutical product liability litigation firm, Carey Danis & Lowe, is currently investigating an alleged Risperdal side effect, male breast growth. In February, the law firm launched an online Risperdal information center. St. Louis, MO (PRWEB) March 11, 2014 The St. Louis pharmaceutical lawyers at Carey Danis & Lowe are currently investigating an alleged Risperdal side effect, male breast growth, medically termed gynecomastia. Carey Danis & Lowe represents plaintiffs who...

2014-03-10 08:29:24

NEW YORK, March 10, 2014 /PRNewswire/ -- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the appointment of Juan Sanchez, M.D., as Vice President of Corporate Communications and Investor Relations. Dr. Sanchez will report to Sharon Mates, Ph.D., CEO and Chairman of Intra-Cellular Therapies. Dr. Sanchez has over ten years of experience as a Wall Street...

2014-03-06 08:30:23

-- Significantly Higher Drug Exposure Achieved with Continued Tolerability -- SEATTLE, March 6, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced additional positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor. Patients with schizophrenia were administered a higher dose than had been evaluated in any OMS824 trial, which resulted in approximately 50 percent higher plasma concentrations than did the...

2014-03-04 23:25:04

The global market for drugs used to treat mental disorders was valued at $70.1 billion in 2012 and is estimated to have declined slightly to nearly $69 billion in 2013. BCC Research projects the market to grow to nearly $77.1 billion by 2018, and register a five-year compound annual growth rate of 2.3% from 2013 to 2018. Wellesley, Mass., (PRWEB) March 04, 2014 According to a new technical market research report Drugs for Treating Mental Disorders: Technologies and Global Markets, from...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related